Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xenotransplantation

Executive Summary

Unanimous approval given by the Biological Response Modifiers Advisory Committee July 30 to a report issued by the Xenotransplantation Subcommittee following its Dec. 7 meeting. At issue was the subcommittee's recommendation that FDA should allow xenotransplant clinical trials; FDA's decision to issue a guidance, due in late 1998, that may streamline clinical trials by establishing requirements for biological assays; the establishment of an electronic registry that would track recipients from transplant to death and also track donor sources; the establishment of a national xenotransplantation advisory committee to keep the public informed; and the committee's desire for worldwide harmonization of regulations governing xenotransplantation
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS032610

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel